Shopping Cart
Remove All
Your shopping cart is currently empty
Sacituzumab govitecan (Synonyms: IMMU-132)
Catalog No. T77824 Copy Product Info
Purity: 95%
🥰Excellent
Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.
Sacituzumab govitecan
Copy Product Info🥰Excellent
Catalog No. T77824
Synonyms IMMU-132
Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.
Sacituzumab govitecan
Cas No. 1491917-83-9
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $455 | In Stock | In Stock | |
| 5 mg | $1,360 | - | In Stock | |
| 10 mg | $1,830 | - | In Stock | |
| 25 mg | $2,730 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.4% (SEC-HPLC)
Appearance:Liquid
Color:Transparent to Yellow
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer. |
| In vivo | Sacituzumab govitecan administered at a dose of 17.5 mg/kg twice weekly for four consecutive weeks showed significant antitumor effects in mice bearing human gastric cancer xenograft tumors. [1] |
| Synonyms | IMMU-132 |
| Reactivity | Human |
| Verified Activity | Immobilized Human TROP2 Protein (ECD, His) at 2 μg/mL (30 μL/well) can bind Sacituzumab govitecan. The EC50 is 0.005813 μg/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1 EU/mg |
| Conjucates | SN38 |
| Uniprot ID | |
| Target | TROP-2 |
| Molecular Weight | 148.74 kDa |
| Cas No. | 1491917-83-9 |
| Isotype | Human IgG1-REM kappa |
| Recommended Isotype Control |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O: 20.00 mg/mL, Sonication is recommended. |
Calculator
Keywords
Preview
Related Tags: buy Sacituzumab govitecan | purchase Sacituzumab govitecan | Sacituzumab govitecan cost | order Sacituzumab govitecan | Sacituzumab govitecan in vivo | Sacituzumab govitecan molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.